Unraveling the Links Between Diabetes, Obesity, and Cardiovascular Disease
2005; Lippincott Williams & Wilkins; Volume: 96; Issue: 11 Linguagem: Inglês
10.1161/01.res.0000170705.56583.45
ISSN1524-4571
Autores Tópico(s)Diabetes, Cardiovascular Risks, and Lipoproteins
ResumoHomeCirculation ResearchVol. 96, No. 11Unraveling the Links Between Diabetes, Obesity, and Cardiovascular Disease Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBUnraveling the Links Between Diabetes, Obesity, and Cardiovascular Disease Paul L. Huang Paul L. HuangPaul L. Huang From the Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Charlestown, Mass. Originally published10 Jun 2005https://doi.org/10.1161/01.RES.0000170705.56583.45Circulation Research. 2005;96:1129–1131Patients with diabetes mellitus are known to be at increased risk for coronary artery disease and myocardial infarction, and have worse outcomes after coronary interventions such as stenting.1 The mechanisms for this increased risk are not fully known, but are thought to reflect vascular abnormalities of inflammation, hypertension, dyslipidemia, and hypercoagulability.2 In turn, these vascular abnormalities may be the result of hyperglycemia, insulin resistance, and advanced glycation products seen in diabetes.3,4 However, the precise molecular links between the metabolic abnormalities seen in diabetes, and the resulting vascular changes that increase propensity for atherosclerosis are not clearly understood.One such link is endothelial dysfunction, seen in diabetes, obesity, hypertension, hyperlipidemia, smoking, and aging.5,6 Endothelial dysfunction is characterized by defects in the normal vascular relaxation response to mediators such as acetylcholine, or to increased blood flow. This can be clinically measured by ultrasound studies of forearm blood flow responses. The basis for endothelial dysfunction may involve a reduction in the amount of bioavailable nitric oxide (NO) in the vasculature. NO is necessary for vascular relaxation and endothelium dependent relaxing factor (EDRF) activity.7,8 NO also serves to suppress atherosclerosis by reducing endothelial cell activation, smooth muscle proliferation, leukocyte activation and leukocyte-endothelial interactions, and platelet aggregation and adhesion.9–12 Therefore, reduction in the amount of bioavailable NO would result in a proatherogenic state.In this issue, Molnar et al describe a mouse model of type 2 diabetes in which they fed C57BL/6 wild-type mice a high- fat diet and sucrose for 9 weeks.13 These mice developed changes consistent with diabetes, including obesity, hyperglycemia, and hyperinsulinemia. The authors found that these mice show marked attenuation of endothelium-dependent vasodilation to acetylcholine. They also demonstrated minor alterations in response to the endothelium-independent vasodilator sodium nitroprusside and in the vasoconstrictor response to phenylephrine. These results confirm that the primary metabolic changes caused by the high-fat and sucrose diet are sufficient to cause abnormalities in vascular function. But what are the mechanisms for these abnormalities?Several pathways may lead to endothelial dysfunction, as outlined in the Figure. First, eNOS mRNA or protein expression levels may be diminished.14 Second, tissue levels of L-arginine, the substrate for NO production, may be limited. An endogenous competitive inhibitor, asymmetric dimethylarginine (ADMA) can reduce endothelial NO production even in the presence of adequate L-arginine levels.15,16 Third, cofactors of eNOS may be limiting: eNOS requires FAD, FMN, NADPH, and BH4 as cofactors. BH4, whose synthesis is rate-limited by GTP cyclohydrolase, is a particularly important cofactor, because in its absence, eNOS can generate superoxide anion.17 Fourth, homodimerization of eNOS may be interrupted. Dimerization of eNOS and its proper intracellular localization to caveolae are mediated in part by interactions with caveolin and hsp90.2,18 Fifth, eNOS is phosphorylated at serine 1179 (S1179) by Akt kinase and other kinases; blockade of Akt decreases eNOS activity.19,20 Sixth, NO produced by eNOS may be rapidly inactivated by reaction with superoxide (O2−) to form peroxynitrite (OONO−).21 This superoxide can be formed by NAD(P)H oxidase,22 or uncoupled eNOS.17 Peroxynitrite is itself a strong oxidant that can damage tissues. Peroxynitrite also nitrosylates tyrosine residues in proteins, a finding by Beckman et al that allows immunohistochemical staining for nitrotyrosine to be used as a surrogate marker for the presence of peroxynitrite.21 These mechanisms are not mutually exclusive, and each of them has been demonstrated in vivo. Download figureDownload PowerPointMechanisms of endothelial dysfunctionPhosphorylation of eNOS at S1179 by Akt kinase appears to be an important step in the regulation of its activity. S1179 phosphorylation activates eNOS, increasing its enzymatic activity and reducing dependence on intracellular calcium.19,23 The protective effects of estrogens24,25 and statins26 act in part through increasing eNOS S1179 phosphorylation. Recent work indicates that PPARγ,27 leptin28,29 and adiponectin30 also modulate eNOS S1179 phosphorylation.Molnar et al examined 2 potential mechanisms for endothelial dysfunction in the mice fed the high fat and sucrose diet: eNOS phosphorylation, and eNOS dimerization.13 Western blot analysis showed that Akt phosphorylation and eNOS S1179 phosphorylation were relatively unaffected by the high-fat and sucrose diet, although there were some minor variations between vascular beds. Thus, in this model at least, abnormalities in eNOS phosphorylation do not appear to account for endothelial dysfunction. Rather, the authors found that eNOS dimerization was nearly absent in the mice fed the high-fat and sucrose diet. In addition, an increase in arterial nitrotyrosine staining suggested an increase in peroxynitrite levels in these animals, providing a possible mechanism for inhibition of dimerization.Endothelial dysfunction is an early step in atherogenesis, and may occur before structural changes in the vasculature. Later steps include vascular injury, accumulation of lipid into foam cells, oxidation of LDL, and the recruitment of inflammatory cells, resulting in development of plaques.31 Molnar et al subjected the diabetic mice to femoral artery denudation, to assess neointimal proliferation in response to vascular injury. This model allows the vascular injury response to be quantitated32 and studied separately from atherosclerotic lesion formation. Mice fed the high-fat and sucrose diet did not show an increase in lesion formation, but actually showed a reduction in lesion burden compared with mice fed a normal diet. This unexpected result underscores that the links between diabetes and atherogenesis are complex, and are not limited to endothelial dysfunction. It shows that endothelial dysfunction can be separated from vascular injury response, in that the former is worse in the high-fat diet fed mice, while the latter is less severe. Although endothelial dysfunction is likely involved in the pathogenesis of arteriosclerosis, this model of diabetes may require additional factors, such as hyperlipidemia or hypercoagulability, to manifest abnormalities in later steps in atherogenesis.This study is an important step in unraveling the complex links between metabolism and vascular abnormalities. The metabolic syndrome is a clinical constellation of glucose intolerance and insulin resistance, obesity, hypertension, hyperlipidemia, inflammation, and hypercoagulability.33 It is likely that the metabolic changes seen in diabetes, obesity, and metabolic syndrome together induce changes in the vasculature that result not only in endothelial dysfunction, but also increased propensity to vascular injury and atherogenesis.34 It remains to be seen how this model compares with other mouse models of diabetes and obesity, for example ob/ob mice (which lack leptin), db/db mice (which lack the leptin receptor), or mouse models of type I diabetes that use islet cell toxins such as streptozotocin or alloxan. Future studies will likely involve combining mouse models of diabetes, such as this one, with other mouse models that provide the additional factors of hyperlipidemia or hypercoagulability, such as Western diet-fed apoE knockout mice or LDL receptor knockout mice.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.P.L.H. is supported by PHS grants HL057818, NS33335, NS048426, and NS010828.FootnotesCorrespondence to Dr Paul L. Huang, Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital East, 149 13th St, Charlestown, MA 02129. E-mail [email protected] References 1 Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol. 2000; 35: 1554–1559.CrossrefMedlineGoogle Scholar2 Gimbrone MA Jr. Endothelial dysfunction and atherosclerosis. J Card Surg. 1989; 4: 180–183.CrossrefMedlineGoogle Scholar3 Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108: 1527–1532.LinkGoogle Scholar4 Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003; 108: 1655–1661.LinkGoogle Scholar5 Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87: 840–844.CrossrefMedlineGoogle Scholar6 Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci. 2000; 902: 230–239;discussion 239–240.CrossrefMedlineGoogle Scholar7 Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem. 1994; 63: 175–195.CrossrefMedlineGoogle Scholar8 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373–376.CrossrefMedlineGoogle Scholar9 Bath PM. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol. 1993; 45: 53–58.CrossrefMedlineGoogle Scholar10 Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb. 1993; 13: 771–776.CrossrefMedlineGoogle Scholar11 Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 1995; 25: 674–678.CrossrefMedlineGoogle Scholar12 Radomski MW, Palmer RM, Moncada S. Modulation of platelet aggregation by an L-arginine-nitric oxide pathway. Trends Pharmacol Sci. 1991; 12: 87–88.CrossrefMedlineGoogle Scholar13 Molnar J, Shuiqing Y, Mzhavia N, Pau C, Chereshnev I, Dansky HM. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high fat diet fed C57BL/6J mice. Circ Res. 2005; 96: 1178–1184.LinkGoogle Scholar14 Wang Y, Marsden PA. Nitric oxide synthases: gene structure and regulation. Adv Pharmacol. 1995; 34: 71–90.CrossrefMedlineGoogle Scholar15 Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun. 1996; 219: 598–603.CrossrefMedlineGoogle Scholar16 Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000; 20: 2032–2037.CrossrefMedlineGoogle Scholar17 Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, Malinski T, Luscher TF. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest. 1998; 101: 1530–1537.CrossrefMedlineGoogle Scholar18 Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol. 2002; 64: 749–774.CrossrefMedlineGoogle Scholar19 Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601–605.CrossrefMedlineGoogle Scholar20 Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001; 299: 818–824.MedlineGoogle Scholar21 Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271: C1424–C1437.CrossrefMedlineGoogle Scholar22 Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000; 20: 2175–2183.CrossrefMedlineGoogle Scholar23 Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597–601.CrossrefMedlineGoogle Scholar24 Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y. Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem. 2001; 276: 3459–3467.CrossrefMedlineGoogle Scholar25 Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000; 87: 677–682.CrossrefMedlineGoogle Scholar26 Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004–1010.CrossrefMedlineGoogle Scholar27 Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem. 2004; 279: 2499–2506.CrossrefMedlineGoogle Scholar28 Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hansch C, Graf K, Nurnberg B, Law RE, Fleck E, Grafe M. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension. 2002; 40: 748–754.LinkGoogle Scholar29 Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile MT, Fratta L, Trimarco V, Trimarco B, Lembo G. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes. 2002; 51: 168–173.CrossrefMedlineGoogle Scholar30 Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003; 278: 45021–45026.CrossrefMedlineGoogle Scholar31 Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340: 115–126.CrossrefMedlineGoogle Scholar32 Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993; 73: 792–796.CrossrefMedlineGoogle Scholar33 Garber AJ. The metabolic syndrome. Med Clin North Am. 2004; 88: 837–846.CrossrefMedlineGoogle Scholar34 Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond). 2004; 107: 519–532.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Roy I, Jover E, Matilla L, Alvarez V, Fernández-Celis A, Beunza M, Escribano E, Gainza A, Sádaba R and López-Andrés N (2023) Soluble ST2 as a New Oxidative Stress and Inflammation Marker in Metabolic Syndrome, International Journal of Environmental Research and Public Health, 10.3390/ijerph20032579, 20:3, (2579) Moscarelli M, Paparella D, Angelini G, Giannini F, Contegiacomo G, Marchese A, Nasso G, Albertini A, Fattouch K and Speziale G (2022) The influence of metabolic syndrome in heart valve intervention. A multi‐centric study, Journal of Cardiac Surgery, 10.1111/jocs.17204, 37:12, (5063-5072), Online publication date: 1-Dec-2022. Gao P, Zou X, Sun X and Zhang C (2022) Cellular Senescence in Metabolic-Associated Kidney Disease: An Update, Cells, 10.3390/cells11213443, 11:21, (3443) Miao R, Fang X, Wei J, Wu H, Wang X and Tian J (2022) Akt: A Potential Drug Target for Metabolic Syndrome, Frontiers in Physiology, 10.3389/fphys.2022.822333, 13 Pryor K, Barbhaiya M, Costenbader K and Feldman C (2021) Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2020.09.004, 47:1, (41-53), Online publication date: 1-Feb-2021. Claro-Cala C, Quintela J, Pérez-Montero M, Miñano J, Alvarez de Sotomayor M, Herrera M and Rodríguez-Rodríguez R (2020) Pomace Olive Oil Concentrated in Triterpenic Acids Restores Vascular Function, Glucose Tolerance and Obesity Progression in Mice, Nutrients, 10.3390/nu12020323, 12:2, (323) Meijer R, Hoevenaars F, Serné E, Yudkin J, Kokhuis T, Weijers E, van Hinsbergh V, Smulders Y and Eringa E (2019) JNK2 in myeloid cells impairs insulin's vasodilator effects in muscle during early obesity development through perivascular adipose tissue dysfunction, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00663.2018, 317:2, (H364-H374), Online publication date: 1-Aug-2019. Čongo S, Gafić E, Pepić F, Biočanin V and Đurić D (2018) Comparative analysis of different definitions of metabolic syndrome, PONS - medicinski casopis, 10.5937/pomc15-17886, 15:2, (86-90), . Zhang X and Lerman L (2017) The metabolic syndrome and chronic kidney disease, Translational Research, 10.1016/j.trsl.2016.12.004, 183, (14-25), Online publication date: 1-May-2017. Rani V, Deep G, Singh R, Palle K and Yadav U (2016) Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies, Life Sciences, 10.1016/j.lfs.2016.02.002, 148, (183-193), Online publication date: 1-Mar-2016. Mao X, Xie L and Greenberg D (2015) Effects of flow on LOX-1 and oxidized low-density lipoprotein interactions in brain endothelial cell cultures, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2015.10.403, 89, (638-641), Online publication date: 1-Dec-2015. Tzanavari T and Karalis K (2015) Stress Proteins and the Adaptive Response of the Heart Introduction to Translational Cardiovascular Research, 10.1007/978-3-319-08798-6_14, (239-251), . Srinivasan V, Ohta Y, Espino J, Zakaria R and Mohamed M (2014) Melatonin's Beneficial Effects in Metabolic Syndrome with Therapeutic Applications Melatonin, 10.1201/b17448-5, (29-48), Online publication date: 30-Sep-2014. Mao X, Xie L, Greenberg R, Greenberg J, Peng B, Mieling I, Jin K and Greenberg D (2014) Flow-induced regulation of brain endothelial cells in vitro, Vascular Pharmacology, 10.1016/j.vph.2014.02.003, 62:2, (82-87), Online publication date: 1-Aug-2014. Amber C, Zeynep T, Evren O, Yusuf B, Can A and Belma T (2014) Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation, Molecular Biology Reports, 10.1007/s11033-014-3392-2, 41:8, (4853-4863), Online publication date: 1-Aug-2014. Pong T, Scherrer-Crosbie M, Atochin D, Bloch K, Huang P and Bauer P (2014) Phosphomimetic Modulation of eNOS Improves Myocardial Reperfusion and Mimics Cardiac Postconditioning in Mice, PLoS ONE, 10.1371/journal.pone.0085946, 9:1, (e85946) Elnakish M, Hassanain H, Janssen P, Angelos M and Khan M (2013) Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase, The Journal of Pathology, 10.1002/path.4255, 231:3, (290-300), Online publication date: 1-Nov-2013. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S and Chattipakorn N (2013) Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injury, International Journal of Cardiology, 10.1016/j.ijcard.2012.01.011, 167:2, (451-457), Online publication date: 1-Jul-2013. Kashiwagi S, Atochin D, Li Q, Schleicher M, Pong T, Sessa W and Huang P (2013) eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2012.12.110, 431:2, (284-290), Online publication date: 1-Feb-2013. Aponte A and Agarwal A (2013) Oxidative Stress Impact on the Fertility of Women with Polycystic Ovary Syndrome Studies on Women's Health, 10.1007/978-1-62703-041-0_10, (169-180), . Zhuo Q, Yang W, Chen J and Wang Y (2012) Metabolic syndrome meets osteoarthritis, Nature Reviews Rheumatology, 10.1038/nrrheum.2012.135, 8:12, (729-737), Online publication date: 1-Dec-2012. Chinda K, Chattipakorn S and Chattipakorn N (2012) Cardioprotective effects of incretin during ischaemia-reperfusion, Diabetes and Vascular Disease Research, 10.1177/1479164112440816, 9:4, (256-269), Online publication date: 1-Oct-2012. Chen G, Xu R, Wang Y, Wang P, Zhao G, Xu X, Gruzdev A, Zeldin D and Wang D (2012) Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy, American Journal of Physiology-Endocrinology and Metabolism, 10.1152/ajpendo.00591.2011, 303:5, (E563-E575), Online publication date: 1-Sep-2012. Gutiérrez-Salmeán G, Ceballos-Reyes G and Ramírez-Sánchez I (2012) Obesity and metabolic syndrome: Future therapeutics based on novel molecular pathways, Clínica e Investigación en Arteriosclerosis, 10.1016/j.arteri.2011.11.002, 24:4, (204-211), Online publication date: 1-Jul-2012. Li Z, Liu J, Liu S, Li X, Yi D, Zhao M and Cignarella A (2012) Improvement of Vascular Function by Acute and Chronic Treatment with the GPR30 Agonist G1 in Experimental Diabetes Mellitus, PLoS ONE, 10.1371/journal.pone.0038787, 7:6, (e38787) Alkharfy K, Al-Daghri N, Al-Attas O, Alokail M, Mohammed A, Vinodson B, Clerici M, Kazmi U, Hussain T and Draz H (2012) Variants of endothelial nitric oxide synthase gene are associated with components of metabolic syndrome in an Arab population, Endocrine Journal, 10.1507/endocrj.EJ11-0278, 59:3, (253-263), . Tesauro M and Cardillo C (2011) Obesity, blood vessels and metabolic syndrome, Acta Physiologica, 10.1111/j.1748-1716.2011.02290.x, 203:1, (279-286), Online publication date: 1-Sep-2011. Atochin D and Huang P (2010) Endothelial nitric oxide synthase transgenic models of endothelial dysfunction, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-010-0867-4, 460:6, (965-974), Online publication date: 1-Nov-2010. Huang P (2009) eNOS, metabolic syndrome and cardiovascular disease, Trends in Endocrinology & Metabolism, 10.1016/j.tem.2009.03.005, 20:6, (295-302), Online publication date: 1-Aug-2009. Ye L, Yu H and Wang G (2009) Determination of exact reconstruction regions in composite-circling cone-beam tomography, Medical Physics, 10.1118/1.3158733, 36:8, (3448-3454), Online publication date: 1-Jul-2009. Huang P (2009) A comprehensive definition for metabolic syndrome, Disease Models & Mechanisms, 10.1242/dmm.001180, 2:5-6, (231-237), Online publication date: 30-Apr-2009. Atkeson A, Yeh S, Malhotra A and Jelic S (2009) Endothelial Function in Obstructive Sleep Apnea, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2008.08.002, 51:5, (351-362), Online publication date: 1-Mar-2009. Quinn C, Hamilton P, Lockhart C and McVeigh G (2009) Thiazolidinediones: effects on insulin resistance and the cardiovascular system, British Journal of Pharmacology, 10.1038/sj.bjp.0707452, 153:4, (636-645), Online publication date: 1-Feb-2008. Atochin D, Wang A, Liu V, Critchlow J, Dantas A, Looft-Wilson R, Murata T, Salomone S, Shin H, Ayata C, Moskowitz M, Michel T, Sessa W and Huang P (2007) The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo, Journal of Clinical Investigation, 10.1172/JCI29877, 117:7, (1961-1967), Online publication date: 2-Jul-2007. Fortuño A, San José G, Moreno M, Beloqui O, Díez J and Zalba G (2006) Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome, Diabetes, 10.2337/diabetes.55.01.06.db05-0751, 55:1, (209-215), Online publication date: 1-Jan-2006. June 10, 2005Vol 96, Issue 11 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000170705.56583.45PMID: 15947251 Originally publishedJune 10, 2005 KeywordshyperlipidemiadiabeteshypercoagulabilityhypertensionobesityPDF download Advertisement
Referência(s)